On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative diseases, such as Alzheimer’s disease (AD), is expected to report ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In “Doctored,” Charles Piller uncovers evidence that many important Alzheimer’s studies are based on faulty data.

Take two at bedtime. That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re ...

ByInvesting.com • Aug 07, 2024 SAVA stock soars to 52-week high, reaching $32.29 Cassava Sciences Inc. (NASDAQ:SAVA) stock has achieved a notable milestone, soaring to a 52-week high of $32.29.

Cassava Sciences is working on bringing its own Alzheimer’s treatment to market to join the new generation of therapies emerging in the area. The company’s CEO, Rick Barry, recently announced ...